For laboratory & research use only. Not for human consumption.
GHRH & Growth Hormone

CJC-1295 + Ipamorelin Blend Mechanism of Action

How a short-acting GHRH analog and a selective ghrelin-receptor agonist act on two separate receptors along the growth hormone axis, and why the pairing produces a pulse rather than a sustained elevation.

Two Receptors, One Axis

Growth hormone release from the pituitary is controlled by two stimulating signals and one inhibiting signal. Growth-hormone-releasing hormone (GHRH) acts on the GHRH receptor; ghrelin acts on the growth hormone secretagogue receptor (GHSR1a); and somatostatin holds release back. This blend combines one compound for each stimulating receptor: a GHRH analog (CJC-1295) and a ghrelin-receptor agonist (Ipamorelin).

Which CJC-1295 Is in This Blend: Without DAC (Mod GRF 1-29)

The name CJC-1295 is used for two different molecules, and the difference matters. Both start from GHRH(1-29), the shortest fully active fragment of GHRH, with four amino-acid substitutions that make it resistant to enzymatic breakdown. CJC-1295 with DAC adds a Drug Affinity Complex linker that binds circulating albumin and stretches the half-life to several days. CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF 1-29, has no albumin linker. KYIN's blend uses the without-DAC form: the current batch certificate identifies the component as CJC-1295 (mod GRF 1-29).

CJC-1295 without DAC (in this blend)CJC-1295 with DAC
Also calledMod GRF 1-29, Modified GRF (1-29)CJC-1295 DAC
Albumin-binding linkerNoYes (maleimidopropionic acid linker)
Duration of actionShort: a discrete pulse of GH releaseLong: days of elevated GH and IGF-1
Release patternPulsatile, close to natural secretionSustained elevation

Because of this, published data for CJC-1295 with DAC, including its multi-day half-life, does not describe the CJC-1295 in this blend. See our CJC-1295 mechanism page for how the DAC version works.

How the Two Components Combine

CJC-1295 (Mod GRF 1-29) binds the GHRH receptor on pituitary somatotroph cells, raising intracellular cyclic AMP and priming GH release. Ipamorelin binds GHSR1a, a different receptor that signals through a separate intracellular pathway, and ghrelin-receptor activation is also described as counteracting somatostatin's inhibitory signal. With one compound pushing through each stimulating receptor, GH-axis research has long studied whether the combination produces a larger pulse than either compound alone. Both components here are short-acting, so the result is a discrete pulse that resembles the body's natural pulsatile pattern rather than a constant elevation.

Why Ipamorelin Rather Than an Older GHRP

Earlier ghrelin-receptor agonists such as GHRP-6 also stimulate GH release, but trigger rises in cortisol, ACTH and prolactin, and GHRP-6 strongly increases appetite. Ipamorelin was engineered for selectivity, activating the GH-release pathway without significantly activating those other hormonal axes. That makes it easier to attribute an observed effect to growth hormone itself. See the Ipamorelin mechanism page for more detail.

  • Dual-receptor (GHRH-R and GHSR1a) growth hormone axis research
  • Pulsatile GH release studies
  • Comparisons of short-acting vs long-acting GHRH analogs
  • Selective secretagogue research

Back to the full CJC-1295 + Ipamorelin Blend research overview →

⚠
Research Use Only Notice This page provides general research and educational context about CJC-1295 + Ipamorelin Blend's mechanism of action only, and does not constitute medical, dosing, or human-use advice. It is not a claim about current regulatory approval, safety, or legal status in any market. Any CJC-1295 + Ipamorelin Blend sourced through KYIN Peptides is sold strictly for laboratory research use by qualified professionals — not for human or animal use, and not intended for diagnostic, therapeutic, or consumption purposes.
FAQ

CJC-1295 + Ipamorelin Blend mechanism questions

Is the CJC-1295 in KYIN's blend with or without DAC?

Without DAC. The current batch certificate identifies the component as CJC-1295 (mod GRF 1-29), the form with no albumin-binding linker, which produces a short pulse of GH release rather than days of sustained elevation.

What is the difference between CJC-1295 with DAC and without DAC?

Both are GHRH(1-29) analogs with four amino-acid substitutions. The DAC version adds an albumin-binding linker that extends its half-life to several days; the no-DAC version (Mod GRF 1-29) lacks the linker and acts briefly, producing a pulsatile GH release.

Why are CJC-1295 and Ipamorelin combined?

They act on two different stimulating receptors on the same axis: CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin receptor (GHSR1a). Research studies the combination to see whether stimulating both pathways produces a larger GH pulse than either compound alone.

Interested in CJC-1295 + Ipamorelin Blend?

RM200 (S$60) for the 5mg + 5mg vial, with a Janoshik certificate covering both components.